An Insight into Advances and Challenges in the Development of Potential Stearoyl Co-A Desaturase 1 Inhibitors

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2024 Sep 25

PMID 39318456

Authors

Shivani Kirad

Sonakshi Puri

P R Deepa

Murugesan Sankaranarayanan

Affiliations

Soon will be listed here.

Abstract

Stearoyl-CoA desaturase 1 (SCD1) is one of the key enzymes involved in lipid metabolism, plays a vital role in the synthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids (SFAs). Due to its promising therapeutic potential in treating metabolic disorders, cancers, and skin diseases there is an increasing interest in the development of novel inhibitors against SCD1. This review comprehensively explores the evolution of potential SCD1 inhibitors, focusing on systemic and liver-targeted inhibitors and discusses their structure-activity relationship (SAR) pattern. Among the various small molecules reported, natural products like sterculic acid have emerged as significant SCD1 inhibitors, highlighting the potential of naturally derived compounds in therapeutic development. This review also addresses the challenges in optimizing pharmacokinetic properties and reducing adverse effects, providing insights into the future directions for the development of potential novel SCD1 inhibitors with maximum therapeutic effect and minimum side effects.

References

Matter H, Zoller G, Herling A, Sanchez-Arias J, Philippo C, Namane C . Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization. Bioorg Med Chem Lett. 2013; 23(6):1817-22. DOI: 10.1016/j.bmcl.2013.01.030. View

Liu G, Lynch J, Freeman J, Liu B, Xin Z, Zhao H . Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J Med Chem. 2007; 50(13):3086-100. DOI: 10.1021/jm070219p. View

Zhang Z, Sun S, Kodumuru V, Hou D, Liu S, Chakka N . Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome. J Med Chem. 2012; 56(2):568-83. DOI: 10.1021/jm301661h. View

Biddinger S, Miyazaki M, Boucher J, Ntambi J, Kahn C . Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes. 2006; 55(7):2032-41. DOI: 10.2337/db05-0742. View

Zou Y, Wang Y, Ma H, He Z, Tang Y, Guo L . SCD1 promotes lipid mobilization in subcutaneous white adipose tissue. J Lipid Res. 2020; 61(12):1589-1604. PMC: 7707166. DOI: 10.1194/jlr.RA120000869. View

Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J . Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021; 27(10):1825-1835. DOI: 10.1038/s41591-021-01495-3. View

Lachance N, Guiral S, Huang Z, Leclerc J, Li C, Oballa R . Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. Bioorg Med Chem Lett. 2011; 22(1):623-7. DOI: 10.1016/j.bmcl.2011.10.070. View

Piccinin E, Cariello M, Moschetta A . Lipid metabolism in colon cancer: Role of Liver X Receptor (LXR) and Stearoyl-CoA Desaturase 1 (SCD1). Mol Aspects Med. 2020; 78:100933. DOI: 10.1016/j.mam.2020.100933. View

Sampath H, Ntambi J . Stearoyl-coenzyme A desaturase 1, sterol regulatory element binding protein-1c and peroxisome proliferator-activated receptor-alpha: independent and interactive roles in the regulation of lipid metabolism. Curr Opin Clin Nutr Metab Care. 2006; 9(2):84-8. DOI: 10.1097/01.mco.0000214564.59815.af. View

10.

Wang C, Shi M, Ji J, Cai Q, Zhao Q, Jiang J . Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging (Albany NY). 2020; 12(15):15374-15391. PMC: 7467382. DOI: 10.18632/aging.103598. View

11.

Zheng Y, Eilertsen K, Ge L, Zhang L, Sundberg J, Prouty S . Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet. 1999; 23(3):268-70. DOI: 10.1038/15446. View

12.

Liu K, Lin L, Li Q, Xue Y, Zheng F, Wang G . Scd1 controls de novo beige fat biogenesis through succinate-dependent regulation of mitochondrial complex II. Proc Natl Acad Sci U S A. 2020; 117(5):2462-2472. PMC: 7007576. DOI: 10.1073/pnas.1914553117. View

13.

Ntambi J . Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res. 1999; 40(9):1549-58. View

14.

Iida T, Ubukata M, Mitani I, Nakagawa Y, Maeda K, Imai H . Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity. Eur J Med Chem. 2018; 158:832-852. DOI: 10.1016/j.ejmech.2018.09.003. View

15.

Bhattacharya D, Basta B, Mato J, Craig A, Fernandez-Ramos D, Lopitz-Otsoa F . Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Rep. 2021; 3(3):100237. PMC: 8189934. DOI: 10.1016/j.jhepr.2021.100237. View

16.

Li F, Gao C, Yan P, Zhang M, Wang Y, Hu Y . EGCG Reduces Obesity and White Adipose Tissue Gain Partly Through AMPK Activation in Mice. Front Pharmacol. 2018; 9:1366. PMC: 6262053. DOI: 10.3389/fphar.2018.01366. View

17.

Uto Y, Kiyotsuka Y, Ueno Y, Miyazawa Y, Kurata H, Ogata T . Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine]. Bioorg Med Chem Lett. 2009; 20(2):746-54. DOI: 10.1016/j.bmcl.2009.11.043. View

18.

Ntambi J . The regulation of stearoyl-CoA desaturase (SCD). Prog Lipid Res. 1995; 34(2):139-50. DOI: 10.1016/0163-7827(94)00010-j. View

19.

Sampath H, Ntambi J . Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr. 2005; 25:317-40. DOI: 10.1146/annurev.nutr.25.051804.101917. View

20.

Bai Y, Zhang T, Hu Z, Zhang Y, Wang D, Zhou M . Sesamin ameliorates nonalcoholic hepatic steatosis by inhibiting CD36-mediated hepatocyte lipid accumulation in vitro and in vivo. Biochem Pharmacol. 2024; 224:116240. DOI: 10.1016/j.bcp.2024.116240. View